{"success":true,"data":{"pressRelease":{"id":"17895","rtpr_id":"nACSh65C0a","ticker":"MEDP","exchange":"NASDAQ","all_tickers":["MEDP"],"title":"Pomerantz LLP Issues Reminder to Investors in Medpace Holdings, Inc.  of Class Action Filing – MEDP","author":"ACCESSWIRE","published_at":"2026-05-02T15:00:00.579Z","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May 2,\n2026 / Pomerantz LLP announces that a class action lawsuit has been filed\nagainst Medpace Holdings, Inc. (\"Medpace\" or the \"Company\")\n(NASDAQ:MEDP).   Such investors are advised to contact Danielle Peyton at\nnewaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980.\nThose who inquire by e-mail are encouraged to include their mailing address,\ntelephone number, and the number of shares purchased.\n\nThe class action concerns whether Medpace and certain of its officers and/or\ndirectors have engaged in securities fraud or other unlawful business\npractices.\n\nYou have until June 8, 2026, to ask the Court to appoint you as Lead Plaintiff\nfor the class if you purchased or otherwise acquired Medpace securities during\nthe Class Period. A copy of the Complaint can be obtained at\nwww.pomerantzlaw.com.        \n\n[Click here for information about joining the class action]\n(https://pomlaw.com/learn-more-form?company=MEDP)\n\nOn February 9, 2026, Medpace released fourth quarter 2025 earnings results,\nrevealing a book-to-bill ratio of 1.04, well below Medpace's guidance.\n\nOn this news, Medpace's stock price fell $84.30 per share, or 15.9%, to close\nat $446.05 per share on February 10, 2026.\n\nPomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris,\nand Tel Aviv, is acknowledged as one of the premier firms in the areas of\ncorporate, securities, and antitrust class litigation. Founded by the late\nAbraham L. Pomerantz, known as the dean of the class action bar, Pomerantz\npioneered the field of securities class actions. Today, more than 85 years\nlater, Pomerantz continues in the tradition he established, fighting for the\nrights of the victims of securities fraud, breaches of fiduciary duty, and\ncorporate misconduct. The Firm has recovered numerous multimillion-dollar\ndamages awards on behalf of class members. See www.pomlaw.com.\n\nAttorney advertising.  Prior results do not guarantee similar outcomes.\n\nSOURCE: Pomerantz LLP\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/pomerantz-llp-issues-reminder-to-investors-in-medpace-holdings-i-1156130)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSh65C0a","title":"Pomerantz LLP Issues Reminder to Investors in Medpace Holdings, Inc.  of Class Action Filing – MEDP","author":"ACCESSWIRE","ticker":"MEDP","created":"2026-05-02T15:00:00.579Z","tickers":["MEDP"],"exchange":"NASDAQ","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May 2,\n2026 / Pomerantz LLP announces that a class action lawsuit has been filed\nagainst Medpace Holdings, Inc. (\"Medpace\" or the \"Company\")\n(NASDAQ:MEDP).   Such investors are advised to contact Danielle Peyton at\nnewaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980.\nThose who inquire by e-mail are encouraged to include their mailing address,\ntelephone number, and the number of shares purchased.\n\nThe class action concerns whether Medpace and certain of its officers and/or\ndirectors have engaged in securities fraud or other unlawful business\npractices.\n\nYou have until June 8, 2026, to ask the Court to appoint you as Lead Plaintiff\nfor the class if you purchased or otherwise acquired Medpace securities during\nthe Class Period. A copy of the Complaint can be obtained at\nwww.pomerantzlaw.com.        \n\n[Click here for information about joining the class action]\n(https://pomlaw.com/learn-more-form?company=MEDP)\n\nOn February 9, 2026, Medpace released fourth quarter 2025 earnings results,\nrevealing a book-to-bill ratio of 1.04, well below Medpace's guidance.\n\nOn this news, Medpace's stock price fell $84.30 per share, or 15.9%, to close\nat $446.05 per share on February 10, 2026.\n\nPomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris,\nand Tel Aviv, is acknowledged as one of the premier firms in the areas of\ncorporate, securities, and antitrust class litigation. Founded by the late\nAbraham L. Pomerantz, known as the dean of the class action bar, Pomerantz\npioneered the field of securities class actions. Today, more than 85 years\nlater, Pomerantz continues in the tradition he established, fighting for the\nrights of the victims of securities fraud, breaches of fiduciary duty, and\ncorporate misconduct. The Firm has recovered numerous multimillion-dollar\ndamages awards on behalf of class members. See www.pomlaw.com.\n\nAttorney advertising.  Prior results do not guarantee similar outcomes.\n\nSOURCE: Pomerantz LLP\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/pomerantz-llp-issues-reminder-to-investors-in-medpace-holdings-i-1156130)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-05-02T15:00:00.61794546Z","server_sent_at_ms":1777734000617},"received_at":"2026-05-02T15:00:00.675Z","source_url":"https://www.accessnewswire.com/newsroom/en/business-and-professional-services/pomerantz-llp-issues-reminder-to-investors-in-medpace-holdings-i-1156130"},"analysis":null,"durationMs":null,"modelName":null}}